Skip to Content

Hypera SA HYPE3

Morningstar Rating
BRL 28.81 −0.61 (2.07%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HYPE3 is trading at a 29% discount.
Price
BRL 29.25
Fair Value
BRL 82.89
Uncertainty
High
1-Star Price
BRL 86.34
5-Star Price
BRL 46.67
Economic Moat
Tzwglt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HYPE3 is a good fit for your portfolio.

Trading Information

Previous Close Price
BRL 29.42
Day Range
BRL 28.5629.66
52-Week Range
BRL 28.5646.84
Bid/Ask
BRL 28.80 / BRL 28.81
Market Cap
BRL 18.24 Bil
Volume/Avg
3.8 Mil / 3.0 Mil

Key Statistics

Price/Earnings (Normalized)
11.58
Price/Sales
2.53
Dividend Yield (Trailing)
2.58%
Dividend Yield (Forward)
1.24%
Total Yield
2.83%

Company Profile

Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and Non-Retail Market.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Core
Total Number of Employees
10,301

Comparables

Valuation

Metric
HYPE3
PGMN3
KNSC11
Price/Earnings (Normalized)
11.5852.618.63
Price/Book Value
1.720.561.00
Price/Sales
2.530.127.46
Price/Cash Flow
12.844.589.64
Price/Earnings
HYPE3
PGMN3
KNSC11

Financial Strength

Metric
HYPE3
PGMN3
KNSC11
Quick Ratio
1.220.3710.00
Current Ratio
1.741.3910.00
Interest Coverage
2.280.48
Quick Ratio
HYPE3
PGMN3
KNSC11

Profitability

Metric
HYPE3
PGMN3
KNSC11
Return on Assets (Normalized)
7.38%−0.16%10.61%
Return on Equity (Normalized)
15.83%−0.58%11.76%
Return on Invested Capital (Normalized)
11.87%6.02%11.55%
Return on Assets
HYPE3
PGMN3
KNSC11
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRWhkyrkdxpdGwnlp$70.5 Bil
ZTS
Zoetis Inc Class ANlqwwjhpWclzy$69.9 Bil
HLN
Haleon PLC ADRXtlkpmgsYjy$36.8 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRSkqgdrwpHtf$14.9 Bil
VTRS
Viatris IncGygkfmnpPtjk$13.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRNdydclbnLdh$12.1 Bil
CTLT
Catalent IncWsbdfdhzQysydl$10.1 Bil
PRGO
Perrigo Co PLCDnxcyjgbgFsmm$4.1 Bil
CURLF
Curaleaf Holdings IncShxnwhfbMnp$3.7 Bil
PBH
Prestige Consumer Healthcare IncQbrzwfmVlbcbj$3.4 Bil

Sponsor Center